|
|
Vol. 22.35 – 25 November, 2024
|
|
|
|
|
|
|
|
Researchers developed MultiPerturb-seq, a high-throughput CRISPR screening platform with joint single-nucleus chromatin accessibility, transcriptome, and guided RNA capture using combinatorial indexing combined with droplet microfluidics to scale throughput and integrate all three modalities. [Nature Biotechnology]
|
|
|
|
|
|
PUBLICATIONSListed by the impact factor of the journal
|
|
|
|
|
|
Scientists revealed that nucleic acid delivery efficacy in macrophages was influenced by phenotype: IL-4-treated “M2-like” macrophages with suppressed mammalian target of rapamycin complex 1 levels were harder-to-transfect than “M1-like” macrophages for mRNA and DNA.
[Advanced Materials]
|
|
|
|
|
|
The authors discovered and characterized AcrIIIA1, the first Type III-A specific anti-CRISPR protein. They showed that AcrIIIA1 bound to Csm2 within the Cas10-Csm effector complex and attenuated Cas10’s DNase activity and second messenger production.
[Nucleic Acids Research]
|
|
|
|
|
|
Scientists showed that single-stranded DNA (ssDNA) with chemical modifications in 12–19% of internal bases improved knock-in by 2–3-fold compared to end-modified ssDNA in airway basal stem cells, CD34+ hematopoietic cells, T cells, and endothelial cells.
[Nucleic Acids Research]
|
|
|
|
|
|
T cells were engineered to co-express NKG2D with a fusion protein that comprised Dap10 joined to a Dap12 endodomain.
[Cell Reports Medicine]
|
|
|
|
|
|
Researchers determined whether MAGE-A4 pMHC-targeted CAR-T cells using the T cell receptor machinery exhibited superior functionality without compromising antigen specificity.
[Journal of Immunotherapy of Cancer]
|
|
|
|
|
|
Scientists explored combination therapy using CD8 T cells engineered to express constitutively active STAT5 with vaccines. CD8 T cells were transduced with a retrovirus encoding the mouse gp100 T cell receptor.
[Molecular Cancer Therapeutics]
|
|
|
|
|
|
When transduced with PCRX-201, the production and release of IL-1Ra was increased in degenerate human nucleus pulposus cells and tissue. [Gene Therapy]
|
|
|
|
|
|
|
|
The authors provide a comprehensive overview of the existing work on immunomodulatory drugs resistance in multiple myeloma, focusing specifically on the emerging evidence of CRBN pathway-independent mechanisms. [Haematologica]
|
|
|
|
|
|
|
|
Vyriad, Inc. announced a strategic collaboration with Novartis to discover and develop in vivo CAR T-cell therapies.
[Vyriad, Inc.]
|
|
|
|
|
|
StemCyte Inc. announced that the US FDA has approved the Biologics License Application for its HPC, Cord Blood product REGENECYTE™, a vital cord blood stem cell therapy for transplantation in patients with blood and immune system disorders. [StemCyte, Inc.]
|
|
|
|
|
|
|
|
|
Dallas, Texas, United States
|
|
|
|
|
|
|
|
|
|
|
City of Hope – Duarte, California, United States
|
|
|
|
|
|
|
Northwell Health – Manhasset, New York, United States
|
|
|
|
|
|
|
University of Lund – Lund, Sweden
|
|
|
|
|
|
|
University of Ostrava – Ostrava, Czech Republic
|
|
|
|
|
|
|
GeneT, University of Coimbra – Coimbra, Portugal
|
|
|
|
|
|